{"_buckets": {"deposit": "62096704-3f2e-42cc-9974-64da6f9051c2"}, "_deposit": {"id": "3738", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "3738"}, "status": "published"}, "_oai": {"id": "oai:soar-ir.repo.nii.ac.jp:00003738", "sets": ["461:462"]}, "author_link": ["6688", "6689", "6690", "6691", "6692", "6693", "6694", "6695", "6696", "6697", "6698", "6699", "6700", "6701"], "item_1628147817048": {"attribute_name": "\u51fa\u7248\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_6_biblio_info_6": {"attribute_name": "\u66f8\u8a8c\u60c5\u5831", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2012-11", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "6", "bibliographicPageEnd": "463", "bibliographicPageStart": "458", "bibliographicVolumeNumber": "13", "bibliographic_titles": [{"bibliographic_title": "CLINICAL LUNG CANCER"}]}]}, "item_6_description_20": {"attribute_name": "\u6284\u9332", "attribute_value_mlt": [{"subitem_description": "The present study was designed to prospectively evaluate the clinical efficacy of gefitinib readministration in patients with advanced non-small cell lung cancer who responded well to initial gefitinib, followed by cytotoxic chemotherapy. Twenty subjects were enrolled, and 3 and 6 patients achieved partial response and stable disease, respectively. These findings provide valuable information for the management of previous gefitinib responders. Introduction: Salvage treatment for acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor in patients with non-small-cell lung cancer is a matter of clinical concern. Several retrospective reports have indicated the usefulness of epidermal growth factor receptor tyrosine kinase inhibitor readministration; however, there have been few prospective studies. Materials and Methods: This study was designed to prospectively evaluate the clinical efficacy of gefitinib readministration in patients with advanced or metastatic non-small-cell lung cancer who responded well to initial gefitinib treatment. The subjects received at least 1 regimen of cytotoxic chemotherapy after progressive disease with the initial gefitinib therapy. Gefitinib administration (250 mg/d, orally) was started after progressive disease with the previous chemotherapeutic regimen. The primary endpoint in the present study was the response rate. Results: Twenty patients were enrolled between April 2007 and May 2011. Three patients achieved partial response, and 6 showed stable disease. Thus, the overall response rate and disease control rate of gefitinib readministration were 15% (95% Cl, 3.21-37.9) and 45% (95% Cl, 23.1-68.5), respectively. Median progression-free survival and overall survival from the start of gefitinib readministration were 2.0 months (95% Cl, 0.9-3.1 months) and 12.0 months (95% Cl, 8.0-16.0 months), respectively. Conclusion: These results suggest that gefitinib readministration may be an option, albeit with a low response rate and short progression-free survival, for patients who responded well to initial gefitinib followed by systemic chemotherapy. These findings provide valuable information for the management of previous gefitinib responders.", "subitem_description_type": "Abstract"}]}, "item_6_description_30": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7\uff08\u30b3\u30f3\u30c6\u30f3\u30c4\u306e\u7a2e\u985e\uff09", "attribute_value_mlt": [{"subitem_description": "Article", "subitem_description_type": "Other"}]}, "item_6_description_5": {"attribute_name": "\u5f15\u7528", "attribute_value_mlt": [{"subitem_description": "CLINICAL LUNG CANCER. 13(6):458-463 (2012)", "subitem_description_type": "Other"}]}, "item_6_link_3": {"attribute_name": "\u4fe1\u5dde\u5927\u5b66\u7814\u7a76\u8005\u7dcf\u89a7\u3078\u306e\u30ea\u30f3\u30af", "attribute_value_mlt": [{"subitem_link_text": "Koizumi, Tomonobu", "subitem_link_url": "http://soar-rd.shinshu-u.ac.jp/profile/ja.WakmHhkh.html"}]}, "item_6_link_67": {"attribute_name": "WoS", "attribute_value_mlt": [{"subitem_link_text": "Web of Science", "subitem_link_url": "http://gateway.isiknowledge.com/gateway/Gateway.cgi?\u0026GWVersion=2\u0026SrcAuth=ShinshuUniv\u0026SrcApp=ShinshuUniv\u0026DestLinkType=FullRecord\u0026DestApp=WOS\u0026KeyUT=000310411400008"}]}, "item_6_publisher_4": {"attribute_name": "\u51fa\u7248\u8005", "attribute_value_mlt": [{"subitem_publisher": "CIG MEDIA GROUP, LP"}]}, "item_6_relation_47": {"attribute_name": "PubMed", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "22402083"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://pubmed.ncbi.nlm.nih.gov/22402083", "subitem_relation_type_select": "PMID"}}]}, "item_6_relation_48": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "10.1016/j.cllc.2012.01.006"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://doi.org/10.1016/j.cllc.2012.01.006", "subitem_relation_type_select": "DOI"}}]}, "item_6_rights_62": {"attribute_name": "\u6a29\u5229", "attribute_value_mlt": [{"subitem_rights": "Copyright\u00a9 2012 Elsevier"}]}, "item_6_select_64": {"attribute_name": "\u8457\u8005\u7248\u30d5\u30e9\u30b0", "attribute_value_mlt": [{"subitem_select_item": "author"}]}, "item_6_source_id_35": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1525-7304", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_39": {"attribute_name": "NII ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1525-7304", "subitem_source_identifier_type": "PISSN"}]}, "item_6_source_id_40": {"attribute_name": "\u66f8\u8a8c\u30ec\u30b3\u30fc\u30c9ID", "attribute_value_mlt": [{"subitem_source_identifier": "AA11973261", "subitem_source_identifier_type": "NCID"}]}, "item_6_text_69": {"attribute_name": "wosonly authkey", "attribute_value_mlt": [{"subitem_text_value": "Chemotherapy; EGFR mutation; Epidermal growth factor receptor tyrosine kinase inhibitor; Gefitinib responder; Non-small-cell lung cancer; Recharrenge"}]}, "item_6_text_70": {"attribute_name": "wosonly keywords", "attribute_value_mlt": [{"subitem_text_value": "TYROSINE KINASE INHIBITORS; EGFR MUTATIONS; ACTIVATING MUTATIONS; CLINICAL BENEFIT; RESISTANCE; ADENOCARCINOMA; DOCETAXEL; TRIAL"}]}, "item_6_textarea_68": {"attribute_name": "wosonly abstract", "attribute_value_mlt": [{"subitem_textarea_value": "The present study was designed to prospectively evaluate the clinical efficacy of gefitinib readministration in patients with advanced non-small cell lung cancer who responded well to initial gefitinib, followed by cytotoxic chemotherapy. Twenty subjects were enrolled, and 3 and 6 patients achieved partial response and stable disease, respectively. These findings provide valuable information for the management of previous gefitinib responders. Introduction: Salvage treatment for acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor in patients with non-small-cell lung cancer is a matter of clinical concern. Several retrospective reports have indicated the usefulness of epidermal growth factor receptor tyrosine kinase inhibitor readministration; however, there have been few prospective studies. Materials and Methods: This study was designed to prospectively evaluate the clinical efficacy of gefitinib readministration in patients with advanced or metastatic non-small-cell lung cancer who responded well to initial gefitinib treatment. The subjects received at least 1 regimen of cytotoxic chemotherapy after progressive disease with the initial gefitinib therapy. Gefitinib administration (250 mg/d, orally) was started after progressive disease with the previous chemotherapeutic regimen. The primary endpoint in the present study was the response rate. Results: Twenty patients were enrolled between April 2007 and May 2011. Three patients achieved partial response, and 6 showed stable disease. Thus, the overall response rate and disease control rate of gefitinib readministration were 15% (95% Cl, 3.21-37.9) and 45% (95% Cl, 23.1-68.5), respectively. Median progression-free survival and overall survival from the start of gefitinib readministration were 2.0 months (95% Cl, 0.9-3.1 months) and 12.0 months (95% Cl, 8.0-16.0 months), respectively. Conclusion: These results suggest that gefitinib readministration may be an option, albeit with a low response rate and short progression-free survival, for patients who responded well to initial gefitinib followed by systemic chemotherapy. These findings provide valuable information for the management of previous gefitinib responders."}]}, "item_creator": {"attribute_name": "\u8457\u8005", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Koizumi,  Tomonobu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6688", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Agatsuma,  Toshihiko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6689", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ikegami,  Kayoko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6690", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Suzuki,  Toshiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6691", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kobayashi,  Takashi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6692", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kanda,  Shintaro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6693", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshikawa,  Sumiko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6694", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kubo,  Keishi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6695", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shiina,  Takayuki", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6696", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Takasuna,  Keiichirou", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6697", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsuo,  Akemi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6698", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hayasaka,  Muneharu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6699", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Morikawa,  Miwa", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6700", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ameshima,  Shingo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "6701", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "\u30d5\u30a1\u30a4\u30eb\u60c5\u5831", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2015-09-24"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "Prospective_study_gefitinib_readministration_after_chemotherapy.pdf", "filesize": [{"value": "392.4 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_note", "mimetype": "application/pdf", "size": 392400.0, "url": {"label": "Prospective_study_gefitinib_readministration_after_chemotherapy.pdf", "url": "https://soar-ir.repo.nii.ac.jp/record/3738/files/Prospective_study_gefitinib_readministration_after_chemotherapy.pdf"}, "version_id": "c368b8d7-98bf-4746-a818-c6bb09377542"}]}, "item_keyword": {"attribute_name": "\u30ad\u30fc\u30ef\u30fc\u30c9", "attribute_value_mlt": [{"subitem_subject": "Chemotherapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "EGFR mutation", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Epidermal growth factor receptor tyrosine kinase inhibitor", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Gefitinib responder", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Non-small-cell lung cancer", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Recharrenge", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "\u8a00\u8a9e", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "\u8cc7\u6e90\u30bf\u30a4\u30d7", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Prospective Study of Gefitinib Readministration After Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer Who Previously Responded to Gefitinib", "item_titles": {"attribute_name": "\u30bf\u30a4\u30c8\u30eb", "attribute_value_mlt": [{"subitem_title": "Prospective Study of Gefitinib Readministration After Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer Who Previously Responded to Gefitinib", "subitem_title_language": "en"}]}, "item_type_id": "6", "owner": "1", "path": ["461/462"], "permalink_uri": "http://hdl.handle.net/10091/17596", "pubdate": {"attribute_name": "PubDate", "attribute_value": "2014-06-12"}, "publish_date": "2014-06-12", "publish_status": "0", "recid": "3738", "relation": {}, "relation_version_is_last": true, "title": ["Prospective Study of Gefitinib Readministration After Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer Who Previously Responded to Gefitinib"], "weko_shared_id": -1}